February 04, 2025

Predicting Response to KRAS G12C Inhibitors in NSCLC

Investigators discovered that measuring the interaction between the RAS and RAF proteins could provide valuable insights into the effectiveness of treatments in patients with KRAS G12C–mutated NSCLC.

The ASCO Post

February 04, 2025

FDA Approves Clinical Trials for Genetically Modified Pig Kidney Transplants

FDA-cleared clinical trials will assess the safety, immunogenicity, and viability of genetically modified pig kidney transplants in patients with end-stage renal disease.

Conexiant

February 04, 2025

FDA Approves First Companion Diagnostic to Identify Patients With Metastatic Breast Cancer Eligible for T-DXd

The FDA has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who may be e...

The ASCO Post

February 01, 2025

Oral Localized Amyloidosis

An encounter with a rare metabolic disorder presents itself as a teachable moment

Inside Dental Hygiene

January 31, 2025

Can Your Eyes Predict Parkinson’s? Retinal Changes May Offer Early Clues

Longitudinal study highlights how subtle retinal alterations could serve as early indicators of Parkinson’s disease progression.

Conexiant

January 29, 2025

Kansas TB Outbreak Grows to 67 Cases

An unprecedented outbreak of Mycobacterium tuberculosis in the Kansas City area has led to the largest recorded cases of TB in recent U.S. history, with significant health implications for the local population.

Reuters

January 28, 2025

Clearance of Driver Mutations after Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis

In a German single-center study reported in The New England Journal of Medicine, Gagelmann et al discussed the clearance of driver mutations after allogeneic hematopoietic stem-cell transplantation (H...

The ASCO Post

January 28, 2025

FDA Approves Enhertu for Metastatic, HR-Positive, HER2-Low or -Ultralow Breast Cancer

Enhertu, a HER2-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration for pretreated patients with metastatic HR-positive, HER2-low or HER2-ultralow breast cancer based on results from the DESTINY-Breast06 trial.

Conexiant

January 27, 2025

New Research Explores Blood Test to Determine Prognosis, Benefit of Celecoxib in Stage III Colon Cancer

Previous research has shown that nonsteroidal antiinflammatory drugs, including aspirin and COX-2 inhibitors, may reduce the risk of developing colon cancer. A recent study from CALGB/SWOG evaluated t...

The ASCO Post